Sign Up Today and Learn More About Enterprise Therapeutics Stock
Invest in or calculate the value of your shares in Enterprise Therapeutics or other pre-IPO companies through EquityZen's platform.

Enterprise Therapeutics Stock (ENTT)
A UK-based developer of drugs to treat respiratory diseases
About Enterprise Therapeutics Stock
Founded
2014
Industries
Software, Artificial Intelligence, Data and Analytics
Enterprise Therapeutics Press Mentions
Stay in the know about the latest news on Enterprise Therapeutics
Eight respiratory disease companies advancing innovative therapies in 2025
labiotech • Mar 01, 2025
Benzodiazolium compounds as enac inhibitors
patents • Feb 08, 2025
10 biotech companies to watch in 2025
labiotech • Dec 17, 2024
Enterprise Therapeutics Publishes on Medicinal Chemistry of ETD001, a Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis
businesswire • Nov 20, 2024
Cystic fibrosis: Five biotechs breathing life into the therapeutic space
labiotech • Nov 08, 2024
Enterprise Therapeutics Management
Leadership team at Enterprise Therapeutics
CSO
Martin Gosling
CEO
John Ford

Join now and verify your accreditation status to gain access to:
- Enterprise Therapeutics Current Valuation
- Enterprise Therapeutics Stock Price
- Enterprise Therapeutics Management
- Available deals in Enterprise Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Enterprise Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Enterprise Therapeutics Revenue and Financials
- Enterprise Therapeutics Highlights
- Enterprise Therapeutics Business Model
- Enterprise Therapeutics Risk Factors
- Enterprise Therapeutics Research Report from SACRA Research
Trading Enterprise Therapeutics Stock
How to invest in Enterprise Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Enterprise Therapeutics through EquityZen funds. These investments are made available by existing Enterprise Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Enterprise Therapeutics stock?
Shareholders can sell their Enterprise Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."